Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Op Grant: Emerging COVID-19 Research Gaps & Priorities - Post COVID-19 condition

Institut de recherches cliniques de Montréal

$0.00

Identification of microbial factors to modulate immune dysregulation and treat post-COVID-19 syndrome.

FY 2021-22

Summary
Post-COVID-19 syndrome represents a new epidemic within the pandemic, affecting potentially more than 330,000 Canadians. While several studies have described post-COVID-19 symptoms, no studies to date have demonstrated the pathophysiological mechanisms underlying these alarming sequelae. Yet, it is precisely this knowledge that will inform post-COVID-19 management and health care resource planning. Previous studies have demonstrated that the composition of the intestinal microbiota in patients with acute COVID-19 is concordant with disease severity and markers of inflammation and tissue damage. Studies in other viral infections such as HIV, have demonstrated that perturbations of the intestinal microbiota and translocation of intestinal bacteria into blood circulation contribute to inflammation and end-organ damage. We hypothesize that perturbations of the intestinal microbiota caused by COVID-19 infection persist for months following infection, leading to leaky gut and bacterial translocation, which results in persistent inflammation and post-COVID-19 manifestations. We have established the first post-COVID-19 research clinic in Montreal and will therefore synergize with our existing infrastructure to address our hypothesis. Through the study of patients with post-COVID-19 syndrome, patients with resolved COVID-19 and patients who tested negative for COVID-19 we will: 1) define the composition and function of the intestinal microbiota; 2) determine if patients with post-COVID-19 syndrome have a leaky gut by evaluating bacterial translocation from the gut into systemic circulation; 3) determine if patients with post-COVID-19 syndrome have increased systemic inflammation and immune dysregulation. This important study will help uncover a mechanism for post-COVID-19 syndrome, while identifying diagnostic markers and bringing forward new therapies such as probiotics or microbially-derived metabolites as a means to treat this debilitating syndrome.
Program
Op Grant: Emerging COVID-19 Research Gaps & Priorities - Post COVID-19 condition
Location
Quebec, Canada
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
448858
Name
Falcone Emilia L
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Public Health Agency of Canada
Instname2
Infection and Immunity
Theme2
Clinical
Prcname2
Operating Grant: Emerging COVID-19 Research Gaps & Priorities - Post COVID-19 condition
Projecttitle
Identification of microbial factors to modulate immune dysregulation and treat post-COVID-19 syndrome.
Programtype2
Operating Grants
Orgnameinp2
Institut de recherches cliniques de Montréal
Cihramount2
$0
Cihrequipment2
$0
Programname2
Op Grant: Emerging COVID-19 Research Gaps & Priorities - Post COVID-19 condition
Keyworddelim
Immune Dysregulation; Inflammation; Metabolome; Microbiota; Post-Covid-19 Condition; Regulatory T Cells
Abstract
Post-COVID-19 syndrome represents a new epidemic within the pandemic, affecting potentially more than 330,000 Canadians. While several studies have described post-COVID-19 symptoms, no studies to date have demonstrated the pathophysiological mechanisms underlying these alarming sequelae. Yet, it is precisely this knowledge that will inform post-COVID-19 management and health care resource planning. Previous studies have demonstrated that the composition of the intestinal microbiota in patients with acute COVID-19 is concordant with disease severity and markers of inflammation and tissue damage. Studies in other viral infections such as HIV, have demonstrated that perturbations of the intestinal microbiota and translocation of intestinal bacteria into blood circulation contribute to inflammation and end-organ damage. We hypothesize that perturbations of the intestinal microbiota caused by COVID-19 infection persist for months following infection, leading to leaky gut and bacterial translocation, which results in persistent inflammation and post-COVID-19 manifestations. We have established the first post-COVID-19 research clinic in Montreal and will therefore synergize with our existing infrastructure to address our hypothesis. Through the study of patients with post-COVID-19 syndrome, patients with resolved COVID-19 and patients who tested negative for COVID-19 we will: 1) define the composition and function of the intestinal microbiota; 2) determine if patients with post-COVID-19 syndrome have a leaky gut by evaluating bacterial translocation from the gut into systemic circulation; 3) determine if patients with post-COVID-19 syndrome have increased systemic inflammation and immune dysregulation. This important study will help uncover a mechanism for post-COVID-19 syndrome, while identifying diagnostic markers and bringing forward new therapies such as probiotics or microbially-derived metabolites as a means to treat this debilitating syndrome.
Competitiondate
202104
Approvedterm2
1 yr 0 mth
Pinamesdelim
Falcone, Emilia L
Approvedterm
1 an 0 mois